Current Chart When the markets are open the data is delayed by 20 minut- es, until 20 minutes after closing. The Growth Stocks You Should Be Buying (at Motley Fool: Mon, 7 Jul 2008 20:51:51 Etc/GMT) Vanda's Drug Draws a Yawn (at Motley Fool: Fri, 27 Jun 2008 19:08:22 Etc/GMT) Neurocrine Pipeline Trickles (Zacks.com: Wed, 18 Jun 2008 12:44:04 Etc/GMT) We have removed all U.S. indiplon revenues from our model, and continue to believe the drugs path to market is going to be extremely difficult. Neurocrine Biosciences Completes 'Petal Study' Treatment Phase for Endometriosis (PR Newswire: Tue, 17 Jun 2008 12:00:00 Etc/GMT) Neurocrine Biosciences, Inc. announced today that the elagolix 0603 Phase IIb trial has completed the 6-month treatment phase. The last subject completed her Week 24 study visit in early June. NEUROCRINE BIOSCIENCES INC Files SEC form 8-K, Other Events (EDGAR Online: Wed, 28 May 2008 21:13:27 Etc/GMT) Neurocrine Biosciences to Present at the 2008 Citi Investment Research Global Health Care Conference (PR Newswire: Mon, 12 May 2008 17:00:00 Etc/GMT) Neurocrine Biosciences, Inc. announced today that Neurocrine Biosciences will present at the Citi Investment Research Global Health Care Conference at the Hilton New York. The live presentation takes place Thursday, May 22, 2008 at 3:00 p.m. Neurocrine Biosciences, Inc. Q1 2008 Earnings Call Transcript (at Seeking Alpha: Mon, 12 May 2008 07:44:48 Etc/GMT) NEUROCRINE BIOSCIENCES INC Financials (EDGAR Online Financials: Wed, 7 May 2008 13:04:59 Etc/GMT)

New Star Analyst Rankings for NEUROCRINE BIOSCI (StarMine: Thu, 1 May 2008 15:14:01 Etc/GMT) NEUROCRINE BIOSCIENCES INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements an (EDGAR Online: Wed, 30 Apr 2008 20:21:24 Etc/GMT) Neurocrine Biosciences Reports First Quarter 2008 Results (PR Newswire: Wed, 30 Apr 2008 20:01:00 Etc/GMT) Neurocrine Biosciences, Inc. today announced its financial results for the quarter ended March 31, 2008. For the first quarter of 2008, the Company reported a net loss of $21.1 million, or $ per share compared with a net loss of $25.7 million, or $ per share, for the same period in 2007. Webcast Alert: Neurocrine Announces 1Q08 Financial Results (PR Newswire: Wed, 30 Apr 2008 11:45:00 Etc/GMT) Neurocrine Biosciences announces the following Webcast: Q1 2008 Neurocrine Biosciences, Inc. Earnings Release - After Market Close (CCBN: Wed, 30 Apr 2008 11:08:21 Etc/GMT) Neurocrine Biosciences Announces Conference Call and Webcast to Present First Quarter 2008 Financial Results (PR Newswire: Mon, 21 Apr 2008 18:00:00 Etc/GMT) Neurocrine Biosciences, Inc. announced today that the Company will report its first quarter 2008 financial results after the Nasdaq market closes on Wednesday, April 30, 2008. Neurocrine will host a live conference call and webcast to discuss its financial results and provide a Company update Wednesday afternoon, April 30, 2008 at 5:00 p.m. Huntington's Therapeutics Reviewed by NeuroInvestment (Marketwire: Wed, 2 Apr 2008 17:58:00 Etc/GMT) NI Research has released the April issue of NeuroInvestment. The issue features a review of Huntington's, a disorder whose monogenic cause and inexorable, horrific course has made it the premier example of why people choose to not have genetic testing. Following the Drugmaker Formerly Known as Neurochem (at Motley Fool: Wed, 2 Apr 2008 14:50:34 Etc/GMT) NEUROCRINE BIOSCIENCES INC Files SEC form 8-K, Change in Directors or Principal Officers (EDGAR Online: Fri, 29 Feb 2008 22:12:16 Etc/GMT) Neurocrine on the Upswing? (at Motley Fool: Wed, 6 Feb 2008 21:21:14 Etc/GMT)

© 2007 stocksmakingthenews.com Powered by Yahoo! Finance